Clinical Trials Directory

Trials / No Longer Available

No Longer AvailableNCT05235347

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

Sotrovimab Expanded Access Treatment Protocol

Status
No Longer Available
Phase
Study type
Expanded Access
Enrollment
Sponsor
Vir Biotechnology, Inc. · Industry
Sex
All
Age
12 Years
Healthy volunteers

Summary

An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.

Conditions

Interventions

TypeNameDescription
BIOLOGICALSotrovimab500mg IV

Timeline

First posted
2022-02-11
Last updated
2022-11-10

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT05235347. Inclusion in this directory is not an endorsement.

Sotrovimab Expanded Access Treatment Protocol (COVID-19) (NCT05235347) · Clinical Trials Directory